North America Sulfonylureas Market Projected to Grow, Hitting USD 3.35 Billion Valuation by 2028 with Notable CAGR of 1.90%


Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "North America Sulfonylureas Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ResearchAndMarkets.com's offering.

The North America Sulfonylureas Market is undergoing a significant growth phase, with an estimated valuation of USD 3.05 billion in 2023. Experts forecast a promising rise to approximately USD 3.35 billion by the year 2028, progressing at a Compound Annual Growth Rate (CAGR) of 1.90% throughout the 2023-2028 period. This market progression highlights the increasing demand and significance of these medications in the effective management of type 2 diabetes.

Surging numbers of diabetes cases in North America, particularly in the United States, have propelled the demand for effective treatment options. The COVID-19 pandemic has further intensified this demand due to the higher risks associated with diabetes patients contracting the virus. Sulfonylureas, as oral anti-diabetic drugs, play a crucial role in stabilizing blood sugar levels, thus gaining traction in the pharmaceutical market

Trends Influencing the North America Sulfonylureas Market Growth

  • Increasing Prevalence of Diabetes: A rise in obesity rates, sedentary lifestyles, and genetic predisposition have led to a growing number of type 2 diabetes cases. This medical condition necessitates effective management tools, such as sulfonylureas, fueling the expansion of the market.

  • Impact of COVID-19: The pandemic underscored the importance of controlling blood glucose levels, especially in high-risk patient populations, thereby boosting the utilization of sulfonylureas during this period.

  • Advancement in Diabetes Care: Ongoing research and developments in diabetes treatment options are paving the way for sulfonylureas as a part of comprehensive diabetes management plans, augmenting their relevance and adoption.

In the United States, the largest market share within North America's sulfonylureas sector has been captured, owing to the rising incidence of diabetes, advanced healthcare infrastructure, and heightened awareness about diabetes management and treatment.

Key Insights into the Sulfonylureas Market Landscape in North America

The marketplace for sulfonylureas in North America presents a fragmented yet competitive arena, with leading pharmaceutical giants and regional players contributing to the dynamic nature of this sector. Medications are widely recognized for their ability to enhance insulin release, offering a vital solution for millions coping with type 2 diabetes. Health insurance coverage, including Medicare, typically encompasses these medications, easing the financial burden on patients and encouraging consistent management of their conditions.

With robust analyst support and detailed market examination, the comprehensive reports available delve into the complexities and potentials of the sulfonylureas market in North America. Such in-depth analysis offers valuable insights for healthcare professionals, stakeholders, and investors interested in the diabetes care industry's future directions.

As diabetes continues to pose significant health challenges in North America, the sulfonylureas market remains at the forefront, offering hope and improved health outcomes for those affected by this chronic disease.

A selection of companies mentioned in this report includes

  • Pfizer
  • Sanofi
  • Mylan
  • Merck
  • Lupin
  • Alembic

For more information about this report visit https://www.researchandmarkets.com/r/rrn08b

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

 

Contact Data